Search all trials

Find therapies in clinical trials near you – page 4

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Small cell lung cancer

Recruiting

Registered drugNo placebo

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Topotecan

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Gemcitabine

Contact Research Centre

Osteosarcoma

Recruiting

Registered drugNo placebo

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cabozantinib

Contact Research Centre

Ovarian cancer recurrent

Recruiting

Registered drugNo placebo

Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Colorectal cancer+2

Recruiting

Registered drugNo placebo

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate

Contact Research Centre

Bladder cancer

Recruiting

Registered drugNo placebo

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin

Contact Research Centre

Gastric cancer+1

Recruiting

Registered drugNo placebo

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azd0901

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

Investigational

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

France

Participants:18–64 years · 65+ years

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

Investigational

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

France

Participants:18–64 years · 65+ years

Contact Research Centre

Mantle cell lymphoma

Recruiting

Registered drug

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Rituximab

Contact Research Centre

Myelofibrosis+1

Recruiting

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ruxolitinib

Contact Research Centre

Find therapies in clinical trials near you – page 4

865 trials match your criteria

Small cell lung cancer

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Pancreatic carcinoma metastatic

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Osteosarcoma

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Ovarian cancer recurrent

Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Colorectal cancer+2

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Pancreatic carcinoma metastatic

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Bladder cancer

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Gastric cancer+1

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Metabolic dysfunction-associated steatohepatitis

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Metabolic dysfunction-associated steatohepatitis

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Mantle cell lymphoma

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Myelofibrosis+1

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.